We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PBH Q4 Earnings & Revenues Miss Estimates, Margins Down
Read MoreHide Full Article
Key Takeaways
PBH posted Q4 adjusted EPS of $1.23 and revenues of $281.6M, both missing consensus estimates.
PBH sales slid as Clear Eyes supply limits hit Eye & Ear Care and Middle East shipping disruptions weighed.
PBH margins sank: gross 51.9% and adjusted op 28.7%; FY27 revenue guided to $1.10-$1.12B.
Prestige Consumer Healthcare Inc. (PBH - Free Report) posted fourth-quarter fiscal 2026 adjusted diluted earnings per share (EPS) of $1.23, down 6.8% from $1.32 a year ago. The figure missed the Zacks Consensus Estimate by 11.7%.
GAAP EPS was $1.13 compared with $1.00 a year ago.
For fiscal 2026, adjusted EPS was $4.38 compared with $4.52 in the previous year.
PBH’s Revenues
Quarterly revenues totaled $281.6 million, down 5.0% year over year. The figure fell short of the Zacks Consensus Estimate by 4.3%.
For fiscal 2026, the company generated total revenues of $1.09 billion, down 4.3% from the prior-year figure.
PBH’s Segmental Performance in Detail
North American OTC Healthcare’s revenues amounted to $234.5 million for the fiscal fourth quarter, down 5.8% year over year. The decrease was primarily due to lower Eye & Ear Care category sales caused by the limited ability to meet demand for Clear Eyes.
International OTC Healthcare’s revenues totaled $47.1 million in the fiscal fourth quarter, down 1% year over year. The weaker revenue performance can be attributed to shipping disruptions in the Middle East and lower sales in the Eye & Ear Care category.
PBH’s Margin Performance
The gross profit in the fiscal fourth quarter fell 13.9% year over year to $146.3 million. The gross margin contracted 539 basis points (bps) year over year to 51.9% due to a 6.5% increase in the cost of sales (excluding depreciation).
During the quarter, advertising and marketing expenses declined 5.2% to $35.1 million, while general and administrative expenses increased 11.9% to $30.3 million. Operating income, excluding depreciation and amortization, totaled $80.9 million, reflecting a 13.4% decrease. The adjusted operating margin contracted 279 bps to 28.7%.
PBH’s Financial Details
Prestige Consumer exited the fiscal fourth quarter of 2026 with cash and cash equivalents of $63.9 million compared with $97.9 million a year ago.
Prestige Consumer generated net cash provided by operating activities of $257.6 million in fiscal 2026, up from $251.5 million in the prior year.
PBH Sets Fiscal 2027 Targets
PBH revealed its fiscal 2027 outlook, projecting revenues in the range of $1.10-$1.12 billion and organic revenue growth in the band of 1-3%. The Zacks Consensus Estimate for revenues is currently pegged at $1.10 billion.
The company expects adjusted diluted earnings per share between $4.42 and $4.51. The Zacks Consensus Estimate was pegged at $4.54 for the metric.
Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise
PBH exited the fiscal fourth quarter of 2026 with weaker-than-expected results, with both earnings and revenues missing estimates. The revenue decline was due to softer Eye & Ear Care results as the company faced a limited ability to meet demand for Clear Eyes. PBH also noted that shipping disruptions in the Middle East affected its quarterly performance, adding to operational pressures late in the period.
Continued strength in Prestige Consumer Healthcare’s Gastrointestinal portfolio, with solid growth from Fleet, Dramamine, and Hydralyte, helped offset the impact of eye care supply constraints. This also supported management’s view that the company’s diversified, category-spanning portfolio can perform through uneven consumer demand.
Prestige Consumer announced an agreement to acquire LaCorium Health for approximately $150 million in cash. The transaction is expected to be closed in the second quarter of fiscal 2027, subject to customary closing conditions.
The contraction of the operating margin is also discouraging.
PBH’s Zacks Rank and Key Picks
Prestige Consumer Health currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Alcon (ALC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Alcon, currently carrying a Zacks Rank #2 (Buy), reported a fourth-quarter 2025 EPS of 78 cents, which missed the Zacks Consensus Estimate by 0.8%. Revenues of $2.70 billion missed the Zacks Consensus Estimate by 0.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ALC has an earnings yield of 2.5% compared to the industry’s negative 1.6% yield. The company’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.11%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted a first-quarter 2026 adjusted EPS of $2.50, which exceeded the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion topped the Zacks Consensus Estimate by 6.2%.
ISRG has an earnings yield of 2.1% in contrast to the industry’s negative yield of 0.9%. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, posted a second-quarter fiscal 2026 adjusted EPS of 87 cents, which outpaced the Zacks Consensus Estimate by 27.01%. Revenues of $373.9 million outperformed the Zacks Consensus Estimate by 4.72%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 20.15%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
PBH Q4 Earnings & Revenues Miss Estimates, Margins Down
Key Takeaways
Prestige Consumer Healthcare Inc. (PBH - Free Report) posted fourth-quarter fiscal 2026 adjusted diluted earnings per share (EPS) of $1.23, down 6.8% from $1.32 a year ago. The figure missed the Zacks Consensus Estimate by 11.7%.
GAAP EPS was $1.13 compared with $1.00 a year ago.
For fiscal 2026, adjusted EPS was $4.38 compared with $4.52 in the previous year.
PBH’s Revenues
Quarterly revenues totaled $281.6 million, down 5.0% year over year. The figure fell short of the Zacks Consensus Estimate by 4.3%.
For fiscal 2026, the company generated total revenues of $1.09 billion, down 4.3% from the prior-year figure.
PBH’s Segmental Performance in Detail
North American OTC Healthcare’s revenues amounted to $234.5 million for the fiscal fourth quarter, down 5.8% year over year. The decrease was primarily due to lower Eye & Ear Care category sales caused by the limited ability to meet demand for Clear Eyes.
International OTC Healthcare’s revenues totaled $47.1 million in the fiscal fourth quarter, down 1% year over year. The weaker revenue performance can be attributed to shipping disruptions in the Middle East and lower sales in the Eye & Ear Care category.
PBH’s Margin Performance
The gross profit in the fiscal fourth quarter fell 13.9% year over year to $146.3 million. The gross margin contracted 539 basis points (bps) year over year to 51.9% due to a 6.5% increase in the cost of sales (excluding depreciation).
During the quarter, advertising and marketing expenses declined 5.2% to $35.1 million, while general and administrative expenses increased 11.9% to $30.3 million. Operating income, excluding depreciation and amortization, totaled $80.9 million, reflecting a 13.4% decrease. The adjusted operating margin contracted 279 bps to 28.7%.
PBH’s Financial Details
Prestige Consumer exited the fiscal fourth quarter of 2026 with cash and cash equivalents of $63.9 million compared with $97.9 million a year ago.
Prestige Consumer generated net cash provided by operating activities of $257.6 million in fiscal 2026, up from $251.5 million in the prior year.
PBH Sets Fiscal 2027 Targets
PBH revealed its fiscal 2027 outlook, projecting revenues in the range of $1.10-$1.12 billion and organic revenue growth in the band of 1-3%. The Zacks Consensus Estimate for revenues is currently pegged at $1.10 billion.
The company expects adjusted diluted earnings per share between $4.42 and $4.51. The Zacks Consensus Estimate was pegged at $4.54 for the metric.
Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise
Prestige Consumer Healthcare Inc. price-consensus-eps-surprise-chart | Prestige Consumer Healthcare Inc. Quote
Our Take
PBH exited the fiscal fourth quarter of 2026 with weaker-than-expected results, with both earnings and revenues missing estimates. The revenue decline was due to softer Eye & Ear Care results as the company faced a limited ability to meet demand for Clear Eyes. PBH also noted that shipping disruptions in the Middle East affected its quarterly performance, adding to operational pressures late in the period.
Continued strength in Prestige Consumer Healthcare’s Gastrointestinal portfolio, with solid growth from Fleet, Dramamine, and Hydralyte, helped offset the impact of eye care supply constraints. This also supported management’s view that the company’s diversified, category-spanning portfolio can perform through uneven consumer demand.
Prestige Consumer announced an agreement to acquire LaCorium Health for approximately $150 million in cash. The transaction is expected to be closed in the second quarter of fiscal 2027, subject to customary closing conditions.
The contraction of the operating margin is also discouraging.
PBH’s Zacks Rank and Key Picks
Prestige Consumer Health currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Alcon (ALC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Alcon, currently carrying a Zacks Rank #2 (Buy), reported a fourth-quarter 2025 EPS of 78 cents, which missed the Zacks Consensus Estimate by 0.8%. Revenues of $2.70 billion missed the Zacks Consensus Estimate by 0.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ALC has an earnings yield of 2.5% compared to the industry’s negative 1.6% yield. The company’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.11%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted a first-quarter 2026 adjusted EPS of $2.50, which exceeded the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion topped the Zacks Consensus Estimate by 6.2%.
ISRG has an earnings yield of 2.1% in contrast to the industry’s negative yield of 0.9%. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, posted a second-quarter fiscal 2026 adjusted EPS of 87 cents, which outpaced the Zacks Consensus Estimate by 27.01%. Revenues of $373.9 million outperformed the Zacks Consensus Estimate by 4.72%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 20.15%.